Efficacy and Safety of Ozanimod in Ulcerative Colitis: A Real-World Pan-Hellenic Study. (PubMed, Medicina (Kaunas)) - Sep 27, 2026 - "Treatment persistence did not differ significantly according to overall prior biologic exposure, whereas previous vedolizumab exposure was associated with lower treatment persistence over the week 48 follow-up (log-rank p = 0.037). Adverse events were reported in 13.9% of patients. Ozanimod demonstrated good efficacy and a favorable safety profile in patients with moderate UC."
Journal • Real-world evidence • Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
|
|
Alexandra Varka; Alexandros Ioannou; Andreas Kapsoritakis; Angeliki Theodoropoulou; Anthia Gatopoulou; Efrosini Laoudi; Eftychia Tsironi; Eirini Zacharopoulou; Evanthia Zampeli; Georgios Axiaris; Georgios Bamias; Georgios Kokkotis; Georgios Leonidakis; Georgios Michalopoulos; Georgios Papatheodoridis; Ioanna Nefeli Mastorogianni; Ioanna Papatzelou; Ioannis Koutroubakis; Ioannis Psaroudakis; Konstantinos Argyriou; Konstantinos Karmiris; Konstantinos Katsanos; Konstantinos Mousourakis; Konstantinos Soufleris; Maria Tzouvala; Nikolaos Kalakos; Nikos Viazis; Olga Giouleme; Panagiotis Markopoulos; Pantelis Karatzas; Pavlos Pardalis; Spyridon Michopoulos; Theodoros Delidis
|